

RECEIVED

OCT 25 2001

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pype et al.

Serial No.: To be assigned

Filed: October 27, 2000

For: CD40-INTERACTING AND TRAF-
INTERACTING PROTEINS

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 4555US

p#6

jc922 U.S. PTO
09/697863
10/27/00

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL700257102US

Date of Deposit with USPS: October 27, 2000

Person making Deposit: Jared Turner

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability

as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

DOCUMENTS

U.S. Patent Documents

Foreign Patent Documents

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
WO 96/16665	06/06/96	PCT
WO 96/16665 (corrected version)	06/06/96	PCT
WO 96/18639	06/20/96	PCT
WO 97/34473	09/25/97	PCT
WO 97/34473 (corrected version)	09/25/97	PCT
WO 98/34946	08/13/98	PCT
WO 98/34946 (corrected version)	08/13/98	PCT
JP 11-75856	03/23/99	Japan
WO 99/33869	07/08/99	PCT

Other Documents

Abstract XP-002115104, Pye et al., 3.13 "Identification of a Novel CD40 Interacting Protein", 1 page.

Abstract XP-002115105, Derwent Publications Ltd., "New Topoisomerase II-binding protein - useful as an anticancer agent", 1 page.

Hanissian et al., "Jak3 Is Associated with CD40 and is Critical for CD40 Induction of Gene Expression in B Cells", Immunity, Vol. 5, pp. 379-387, April, 1997.

PCT International Search Report, PCT/EP99/03025, dated September 30, 1999, 8 pages.

PCT International Preliminary Examination Report, PCT/EP99/03025, dated July 24, 2000.

Rothe et al., "A Novel Family of Putative Signal Transducers Associated with the Cytoplasmic Domain of the 75 kDa Tumor Necrosis Factor Receptor", Cell, Vol. 78, pp. 681-692, August 26, 1994.

Yang et al., "Daxx, a Novel Fas-Binding Protein That Activates JNK and Apoptosis", Cell, Vol. 89, pp. 1067-1076, June 27, 1997.

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. 1.17(p) is required.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASK BRITT
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: October 27, 2000

ACT/le

Enclosures: Form PTO-1449
Copy of documents cited